Surveillance Research Program, American Cancer Society, 250 Williams St NW, Atlanta, GA 30303, USA.
J Natl Cancer Inst. 2013 Feb 6;105(3):175-201. doi: 10.1093/jnci/djs491. Epub 2013 Jan 7.
The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate annually to provide updates on cancer incidence and death rates and trends in these outcomes for the United States. This year's report includes incidence trends for human papillomavirus (HPV)-associated cancers and HPV vaccination (recommended for adolescents aged 11-12 years).
Data on cancer incidence were obtained from the CDC, NCI, and NAACCR, and data on mortality were obtained from the CDC. Long- (1975/1992-2009) and short-term (2000-2009) trends in age-standardized incidence and death rates for all cancers combined and for the leading cancers among men and among women were examined by joinpoint analysis. Prevalence of HPV vaccination coverage during 2008 and 2010 and of Papanicolaou (Pap) testing during 2010 were obtained from national surveys.
Death rates continued to decline for all cancers combined for men and women of all major racial and ethnic groups and for most major cancer sites; rates for both sexes combined decreased by 1.5% per year from 2000 to 2009. Overall incidence rates decreased in men but stabilized in women. Incidence rates increased for two HPV-associated cancers (oropharynx, anus) and some cancers not associated with HPV (eg, liver, kidney, thyroid). Nationally, 32.0% (95% confidence interval [CI] = 30.3% to 33.6%) of girls aged 13 to 17 years in 2010 had received three doses of the HPV vaccine, and coverage was statistically significantly lower among the uninsured (14.1%, 95% CI = 9.4% to 20.6%) and in some Southern states (eg, 20.0% in Alabama [95% CI = 13.9% to 27.9%] and Mississippi [95% CI = 13.8% to 28.2%]), where cervical cancer rates were highest and recent Pap testing prevalence was the lowest.
The overall trends in declining cancer death rates continue. However, increases in incidence rates for some HPV-associated cancers and low vaccination coverage among adolescents underscore the need for additional prevention efforts for HPV-associated cancers, including efforts to increase vaccination coverage.
美国癌症协会(ACS)、疾病控制与预防中心(CDC)、国家癌症研究所(NCI)和北美癌症登记协会(NAACCR)每年合作,提供美国癌症发病率、死亡率以及这些结局的趋势的最新信息。今年的报告包括人乳头瘤病毒(HPV)相关癌症和 HPV 疫苗接种(推荐给 11-12 岁青少年)的发病率趋势。
癌症发病率数据来自 CDC、NCI 和 NAACCR,死亡率数据来自 CDC。通过 Joinpoint 分析,对所有癌症和男性及女性主要癌症的长期(1975/1992-2009 年)和短期(2000-2009 年)年龄标准化发病率和死亡率趋势进行了检查。2008 年和 2010 年 HPV 疫苗接种率以及 2010 年巴氏涂片检查率来自全国调查。
男性和女性所有主要种族和族裔群体以及大多数主要癌症部位的所有癌症死亡率继续下降;2000 年至 2009 年期间,两性综合死亡率每年下降 1.5%。总体发病率在男性中下降,在女性中稳定。两种 HPV 相关癌症(口咽、肛门)和一些与 HPV 无关的癌症(如肝脏、肾脏、甲状腺)的发病率增加。2010 年,全国有 32.0%(95%置信区间[CI] = 30.3%至 33.6%)13 至 17 岁的女孩接种了三剂 HPV 疫苗,未参保者(14.1%,95%CI = 9.4%至 20.6%)和某些南部州(如阿拉巴马州[95%CI = 13.9%至 27.9%]和密西西比州[95%CI = 13.8%至 28.2%])的覆盖率较低,这些州的宫颈癌发病率最高,最近巴氏涂片检查的普及率最低。
癌症死亡率总体呈下降趋势。然而,某些 HPV 相关癌症的发病率上升和青少年 HPV 疫苗接种率低,突显了需要加强 HPV 相关癌症的预防工作,包括增加疫苗接种率。